Covid-19 has swept the globe, changing the way we view the world, probably forever. Nearly 34 million people have been infected with the virus. Over a million deaths have been recorded so far.
The pharmaceutical industry has been stung into action to develop both preventative and therapeutic interventions: presently 3,438 clinical studies are underway worldwide and 625 drugs and vaccines are in development.
Clearly, time is not our friend in the fight against the pandemic, which is why methods that accelerate the development of research procedures are of critical importance. In light of this, global biotech company GenScript, which specializes in custom monoclonal antibody generation, has utilized the cutting-edge optofluidic technology of the Beacon® B cell sorting platform and the power of rabbit monoclonal antibodies (mAbs) to develop effective solutions.
Using this technology, GenScript discovered several Covid-19 spike protein antibodies that target the receptor-binding domain of SARS-CoV-2 Spike protein, the mode of action of which enables the virus to infect cells.
Two technologies combined in the fight against Covid-19
Increasingly, the distinct advantages of rabbit mAbs have led to their greater use in all areas of life sciences, from basic research to diagnostics and therapeutics.
Consequently, GenScript developed MonoRab™, a proprietary rabbit antibody generation platform,
The post Antibodies: A Beacon of Hope During the Covid-19 Pandemic Dark Days? appeared first on Labiotech.eu.
Published on Wed, 07 Oct 2020 08:00:58 +0000 in support of nintex sort collection